Esperion Therapeutics (NASDAQ: ESPR) reported Q2 EPS of ($2.01), $0.15 worse than the analyst estimate of ($1.86). Revenue for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE